Investment Banking
Co-Lead Manager on Inhibikase Therapeutics’ $115.0MM CMPO
December 01, 2025
Oppenheimer & Co. Inc. acted as Co-Lead Manager on Inhibikase Therapeutics’ $115.0MM Confidentially Marketed Public Offering
Inhibikase Therapeutics, Inc. (“Inhibikase”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), announced the pricing of its underwritten public offering of $115.0M shares of common stock and pre-funded warrants.
Inhibikase intends to use the net proceeds from this offering primarily for general corporate purposes, which may include, among other things, clinical trials, product candidate development and manufacturing activities for IKT-001 and other product candidates, other research and development activities, acquisitions of new technologies or businesses, capital expenditures, selling, general and administrative costs, and to meet working capital needs.
Healthcare Life Sciences Investment Banking
Name:
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Head of Healthcare Life Sciences Investment Banking
Healthcare Equity Capital Markets
Name:
Andy Linderman
Title:Managing Director, Healthcare Capital Markets Investment Banking
Name:
James Yoo
Title:Managing Director, Healthcare Capital Markets Investment Banking
DISCLOSURES
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
Oppenheimer & Co. Inc. Transacts Business on all Principal US Exchanges and is a Member of SIPC 8634167.1